



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

November 26, 2012

Via E-mail

Daniel P. Gold  
President and Chief Executive Officer  
MEI Pharma, Inc.  
11975 El Camino Real, Suite 101  
San Diego, CA 92130

**Re: MEI Pharma, Inc.  
Preliminary Information Statement on Schedule 14C  
Filed November 9, 2012  
File No. 000-50484**

Dear Mr. Gold:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Jeffrey P. Riedler

Jeffrey P. Riedler  
Assistant Director

cc: Via E-mail  
Finnbarr D. Murphy  
Morgan, Lewis & Bockius LLP